Breast Cancer

Stiffness and hypoxia environments triggers the spread of breast cancer.

Pevonedistat, currently being tested in clinical trials, shows promise in killing melanomas and other cancer types.

New mouse study suggests that exposure to endocrine disrupting chemicals may cause resistance to tamoxifen therapy in some breast cancers.

High body mass index linked to 10 types of cancer, including cancers of the breast, bowel, esophageal, and womb.

Immunotherapy able to kill triple-negative breast cancer cells via two-pronged strategy.

Higher levels of transport genes are an indicator of patients likely to be resistant to therapy with tamoxifen.

Experimental drug shows promise killing triple negative breast cancer cells.

Little clinical data exists to aid shared decision making for mammography frequency.

Nebivolol shows promise blocking anthracycline-induced cardiotoxicity in breast cancer patients.

Patients with negative expectations about breast cancer treatment had nearly twice the amount of side effects.

Genetic mechanisms could potentially promote cancer growth and spread.

Expanded use of bundled payments in cancer for services such as mammography.

Some breast cancer tumors are not sensitive to Herceptin.

Duration and degree of being overweight impacts cancer risk in postmenopausal women.

Researchers examine whether cognitive impairment caused by chemotherapy drugs in breast cancer patients is a long-term issue.

Breast cancer patients who expected significant side effects from adjuvant hormone therapy reported worse adverse events.

Researchers advance understanding of how breast cancer drugs work inside human cells.

A consensus about margins could reduce healthcare costs for patients with ductal carcinoma in-situ.

Hormone receptor testing may be unnecessary in breast cancer patients.

Aromatase inhibitors in human estrogen-receptor positive breast cancer can cause tumor mutations.

Obesity becoming a growing health concern for cancer survivors, specifically breast and colorectal cancers.

Increased genetic knowledge about non-whites could lead to improved knowledge and treatments.

Bacterial differences were seen between tissue from patients with and without breast cancer.

Drug to be evaluated combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Ribociclib seeking indication for use in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.